prasugrel

(redirected from Effient)
Also found in: Medical.
Related to Effient: efficient
Translations

prasugrel

n prasugrel m
References in periodicals archive ?
Assess products, including these: -- Plavix -- Lovenox -- Xarelto -- Pradaxa -- Activase -- Effient -- Aspirin Cardio -- Pletal.
Medicines forecasted and discussed include Plavix, Lovenox, Xarelto, Pradaxa, Activase, Effient, Aspirin Cardio and Pletal.
of 2013, worldwide Effient sales increased 11 percent to $508.
Lilly last week said that its sales representatives would tell doctors about a blood test offered by Accumetrics that physically measures clotting ability after patients take anti-platelet drugs like Effient and Plavix.
Drug maker Daiichi Sankyo climbed 51 yen, or over 3 percent, to 1,714 yen after its drug Effient, which prevents blood clots, received U.
Registered trademarks: Coumadin (Bristol-Myers Squibb), Plavix (Sanofi), Effient (Eli Lilly and Company), Brilinta (AstraZeneca group of companies).
hydrochloride, Lilly) Effient (prasugrel, Lilly) Evista (raloxifene
However, sales of Lilly's widely anticipated blood thinner Effient slid to $3.
Cartledge, MD, FACS, has begun performing ultra-minimally invasive left atrial appendage ligation for atrial fibrillation patients who are on anticoagulants such as Coumadin, Xarelto or Effient.
Assess products including these: -- Plavix -- Lovenox -- Pradaxa -- Xarelto -- Activase -- Effient.
Lilly delivered solid financial results in the fourth quarter of 2012, as we successfully offset a large part of the revenue decline from the Zyprexa patent expiration with growth in other products such as Cymbalta, Forteo, Alimta, Effient and our animal health portfolio," said John C.
This publication provides an overview of the clinical efficacy and safety of Effient[R] (prasugrel), Effient is indicated to reduce the rate of thrombotic cardiovascular (CV) events (including stent thrombosis) in patients with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI) as follows: 1) Patients with unstable angina (UA) or non-ST-elevation myocardial infarction (NSTEMI), 2) Patients with ST-elevation myocardial infarction (STEMI) when managed with primary or delayed PCI.